The Regulatory Accountability Act of 2017 — Implications for FDA Regulation and Public Health image

NEJM, February 1, 2018
Jonathan J. Darrow (Student Fellow Alumnus), Erin C. Fuse Brown, and Aaron S. Kesselheim


Read the full article

From the article:

In the past year, federal health policy has been characterized by pervasive uncertainty, but a consistent theme from the Trump administration and some prominent legislators has been opposition to regulation. Last spring, Congress took a substantial step toward making regulation by federal agencies more difficult in all areas, including health. The Regulatory Accountability Act1 — which passed through the committee phase in the Senate in May, after the House of Representatives passed a similar bill — has been described by proponents as a way to reverse the increasing volume of regulatory requirements. Supporters in the Senate claim that such requirements stifle economic growth, reduce jobs, and place U.S. businesses at a disadvantage relative to foreign competitors. But the bill would pursue its deregulatory aims by imposing onerous requirements on rulemaking, which we believe could have potentially disastrous consequences for the Food and Drug Administration (FDA) and other agencies that protect public health and safety.

Read more here!

fda health law policy pharmaceuticals public health regulation